Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

REGENXBIO Inc. RGNX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$26.00
+179.6%

REGENXBIO Inc. (RGNX) is a Biotechnology company in the Healthcare sector, currently trading at $9.30. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is RGNX = $26 (+179.6% upside).

Valuation: RGNX trades at a trailing Price-to-Earnings (P/E) of -2.3 (S&P 500 average ~25).

Financials: revenue is $170M, +25.6%/yr average growth. Net income is $194M (loss), growing at +11.5%/yr. Net profit margin is -113.8% (negative). Gross margin is 88.1% (+36.5 pp trend).

Balance sheet: total debt is $261M against $103M equity (Debt-to-Equity (D/E) ratio 2.54, leveraged). Current ratio is 2.38 (strong liquidity). Debt-to-assets is 57.5%. Total assets: $453M.

Analyst outlook: 14 / 20 analysts rate RGNX as buy (70%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 58/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).

$26.00
▲ 179.57% Upside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for REGENXBIO Inc., the average price target is $26.00, with a high forecast of $45.00, and a low forecast of $12.00.
Highest Price Target
$45.00
Average Price Target
$26.00
Lowest Price Target
$12.00

RGNX SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RGNX

✓
VALUE Pass
100/100
RGNX trades at a trailing Price-to-Earnings (P/E) of -2.3 (S&P 500 average ~25). Forward PEG -0.08 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.28. Analyst consensus target is $26, implying +179.6% from the current price $9. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
RGNX: +25.6%/yr revenue is, +11.5%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet RGNX: Debt-to-Equity (D/E) ratio 2.54 (leveraged), Current ratio is 2.38 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
RGNX: Gross margin is 88.1% (+36.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 14 / 20 analysts rate RGNX as buy (70%). Analyst consensus target is $26 (+179.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
RGNX: Net profit margin is -113.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.035-16.19
Volume567.34K
Avg Volume (30D)976.65K
Market Cap$480M
Beta (1Y)1.13
Share Statistics
EPS (TTM)-3.76
Shares Outstanding$51.57M
IPO Date2015-09-17
Employees353
CEOCurran Simpson
Financial Highlights & Ratios
Revenue (TTM)$170.44M
Gross Profit$150.14M
EBITDA$-145.58M
Net Income$-193.88M
Operating Income$-161.2M
Total Cash$230.07M
Total Debt$260.52M
Net Debt$226.05M
Total Assets$453.03M
Price / Earnings (P/E)-2.5
Price / Sales (P/S)2.82
Analyst Forecast
1Y Price Target$23.50
Target High$45.00
Target Low$12.00
Upside+152.7%
Rating ConsensusBuy
Analysts Covering20
Buy 70% Hold 25% Sell 5%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS75901B1070

Price Chart

Track all markets on TradingView
RGNX
REGENXBIO Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
5.04 52WK RANGE 16.19

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 MIRM
MIRM
Mirum Pharmaceuticals, Inc.
$96.90
+0.42%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 IMCR
IMCR
Immunocore Holdings plc
$31.69
+0.70%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message